Johns Hopkins Develops Urine-Based Biomarker Panel for Prostate Cancer Detection with 91% Accuracy
核心洞察
Johns Hopkins researchers developed a novel three-biomarker urine panel (TTC3 (搜索), H4C5 (搜索), and EPCAM (搜索)) that detects prostate cancer with 91% sensitivity and 84% specificity.
The panel significantly outperformed existing urinary PCA3 (搜索) RNA testing, achieving an area under the curve of 0.92 compared to 0.76 for PCA3 in validation studies.
The test successfully diagnosed prostate cancer in 86% of PSA (搜索)-negative cases and distinguished cancer from benign conditions like prostatitis with 84-89% accuracy.
Johns Hopkins researchers have developed a promising urine-based biomarker panel that demonstrates significant accuracy in detecting prostate cancer, potentially offering a noninvasive alternative to current screening methods. The three-biomarker panel achieved 91% sensitivity in identifying prostate cancer cases and 84% specificity in ruling out individuals without the disease.
Novel Biomarker Discovery and Validation
The research team, led by Dr. Ranjan Perera, Director of the Center for RNA Biology at Johns Hopkins All Children's Hospital, conducted RNA sequencing analysis of exfoliated cells in urine specimens to identify potential biomarkers. From an initial pool of 50 candidate RNAs, investigators narrowed down the selection using quantitative polymerase chain reaction testing to identify three biomarkers with optimal specificity and sensitivity: TTC3 (搜索), H4C5 (搜索), and EPCAM (搜索).
"This new biomarker panel offers a promising, sensitive, specific, noninvasive diagnostic test for prostate cancer," stated Dr. Perera. "It has the potential to accurately detect prostate cancer, reduce unnecessary biopsies, improve diagnostic accuracy in prostate-specific antigen (PSA (搜索))-negative patients, and serve as the foundation for both laboratory-developed and in vitro diagnostic assays."
Superior Performance Compared to Existing Tests
The study, published in eBioMedicine, analyzed urine samples from almost 900 individuals in a case-control study split into development and validation datasets. Participants included patients with prostate cancer both before and after prostatectomy, as well as healthy individuals.
In the development dataset, the three-biomarker panel achieved an area under the curve of 0.96 (95% confidence interval = 0.94–0.98) compared to 0.83 (95% CI = 0.77–0.88) for urinary PCA3 (搜索) RNA. The validation dataset confirmed these superior results, with the novel panel achieving an area under the curve of 0.92 (95% CI = 0.89–0.94) versus 0.76 (95% CI = 0.72–0.80) for PCA3.
Clinical Applications and Diagnostic Accuracy
The biomarker panel demonstrated particular promise in challenging diagnostic scenarios. It successfully diagnosed prostate cancer in PSA (搜索)-negative cases 86% of the time in the validation set, addressing a significant gap in current screening capabilities. Additionally, the test distinguished prostate cancer from benign prostate conditions, including prostatitis and benign prostatic hyperplasia, with 84% to 89% accuracy.
Post-prostatectomy analysis confirmed that the urine biomarkers were almost completely eliminated following surgery and originated in prostate tissue at both RNA and protein levels, validating their specificity to prostate cancer.
Addressing Current Screening Limitations
"There is a real need for non–PSA (搜索)-based biomarkers for prostate cancer, and urine is quite easy to collect in the clinic," explained study co-author Dr. Christian Pavlovich, the Bernard L. Schwartz Distinguished Professor of Urologic Oncology at Johns Hopkins. "Most urologists feel that an accurate urinary biomarker would be a valuable addition to our current diagnostic armamentarium."
Current prostate cancer screening relies heavily on PSA (搜索) testing despite its limited accuracy, creating a need for more precise diagnostic tools.
Therapeutic Implications and Future Development
Beyond diagnostic applications, functional studies revealed that depletion of TTC3 (搜索) could suppress tumor growth both in vitro and in vivo, suggesting potential therapeutic targets. The overall diagnostic accuracy of the panel ranged from 78.6% to 85.7% across different study populations.
Dr. Vipul Patel, Director of Urologic Oncology at AdventHealth Cancer Institute (搜索) and study co-author, emphasized the clinical potential: "This test has the potential to help physicians improve diagnostic accuracy of prostate cancer, reducing unnecessary interventions while allowing early treatment for those who need it. On behalf of physicians and patients globally, I advocate for further study and progress for these biomarkers."